Literature DB >> 35000421

MiR-150 Attenuates Maladaptive Cardiac Remodeling Mediated by Long Noncoding RNA MIAT and Directly Represses Profibrotic Hoxa4.

Tatsuya Aonuma1,2, Bruno Moukette1, Satoshi Kawaguchi1, Nipuni P Barupala1, Marisa N Sepúlveda1, Kyle Frick3, Yaoliang Tang4, Maya Guglin3, Subha V Raman3, Chenleng Cai5, Suthat Liangpunsakul6,7, Shinichi Nakagawa8, Il-Man Kim1,3,5.   

Abstract

BACKGROUND: MicroRNA-150 (miR-150) plays a protective role in heart failure (HF). Long noncoding RNA, myocardial infarction-associated transcript (MIAT) regulates miR-150 function in vitro by direct interaction. Concurrent with miR-150 downregulation, MIAT is upregulated in failing hearts, and gain-of-function single-nucleotide polymorphisms in MIAT are associated with increased risk of myocardial infarction (MI) in humans. Despite the correlative relationship between MIAT and miR-150 in HF, their in vivo functional relationship has never been established, and molecular mechanisms by which these 2 noncoding RNAs regulate cardiac protection remain elusive.
METHODS: We use MIAT KO (knockout), Hoxa4 (homeobox a4) KO, MIAT TG (transgenic), and miR-150 TG mice. We also develop DTG (double TG) mice overexpressing MIAT and miR-150. We then use a mouse model of MI followed by cardiac functional, structural, and mechanistic studies by echocardiography, immunohistochemistry, transcriptome profiling, Western blotting, and quantitative real-time reverse transcription-polymerase chain reaction. Moreover, we perform expression analyses in hearts from patients with HF. Lastly, we investigate cardiac fibroblast activation using primary adult human cardiac fibroblasts and in vitro assays to define the conserved MIAT/miR-150/HOXA4 axis.
RESULTS: Using novel mouse models, we demonstrate that genetic overexpression of MIAT worsens cardiac remodeling, while genetic deletion of MIAT protects hearts against MI. Importantly, miR-150 overexpression attenuates the detrimental post-MI effects caused by MIAT. Genome-wide transcriptomic analysis of MIAT null mouse hearts identifies Hoxa4 as a novel downstream target of the MIAT/miR-150 axis. Hoxa4 is upregulated in cardiac fibroblasts isolated from ischemic myocardium and subjected to hypoxia/reoxygenation. HOXA4 is also upregulated in patients with HF. Moreover, Hoxa4 deficiency in mice protects the heart from MI. Lastly, protective actions of cardiac fibroblast miR-150 are partially attributed to the direct and functional repression of profibrotic Hoxa4.
CONCLUSIONS: Our findings delineate a pivotal functional interaction among MIAT, miR-150, and Hoxa4 as a novel regulatory mechanism pertinent to ischemic HF.

Entities:  

Keywords:  RNA, untranslated; carvedilol; fibroblasts; microRNAs; transcriptome

Mesh:

Substances:

Year:  2022        PMID: 35000421      PMCID: PMC9018469          DOI: 10.1161/CIRCHEARTFAILURE.121.008686

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   10.447


  78 in total

1.  Combinatorial microRNA target predictions.

Authors:  Azra Krek; Dominic Grün; Matthew N Poy; Rachel Wolf; Lauren Rosenberg; Eric J Epstein; Philip MacMenamin; Isabelle da Piedade; Kristin C Gunsalus; Markus Stoffel; Nikolaus Rajewsky
Journal:  Nat Genet       Date:  2005-04-03       Impact factor: 38.330

2.  MicroRNA-150 Protects Against Pressure Overload-Induced Cardiac Hypertrophy.

Authors:  Wanli Liu; Yu Liu; Yan Zhang; Xueyong Zhu; Rui Zhang; Lihua Guan; Qizhu Tang; Hong Jiang; Congxin Huang; He Huang
Journal:  J Cell Biochem       Date:  2015-10       Impact factor: 4.429

3.  Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia.

Authors:  H A Drabkin; C Parsy; K Ferguson; F Guilhot; L Lacotte; L Roy; C Zeng; A Baron; S P Hunger; M Varella-Garcia; R Gemmill; F Brizard; A Brizard; J Roche
Journal:  Leukemia       Date:  2002-02       Impact factor: 11.528

4.  Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors.

Authors:  Muhammad S Beg; Andrew J Brenner; Jasgit Sachdev; Mitesh Borad; Yoon-Koo Kang; Jay Stoudemire; Susan Smith; Andreas G Bader; Sinil Kim; David S Hong
Journal:  Invest New Drugs       Date:  2016-12-05       Impact factor: 3.850

5.  Myocardial Infarction-Associated Transcript, a Long Noncoding RNA, Is Overexpressed During Dilated Cardiomyopathy Due to Chronic Chagas Disease.

Authors:  Amanda Farage Frade; Laurie Laugier; Ludmila Rodrigues Pinto Ferreira; Monique Andrade Baron; Luiz Alberto Benvenuti; Priscila Camillo Teixeira; Isabela Cunha Navarro; Sandrine Cabantous; Frederico Moraes Ferreira; Darlan da Silva Cândido; Fabio Antônio Gaiotto; Fernando Bacal; Pablo Pomerantzeff; Ronaldo Honorato Barros Santos; Jorge Kalil; Edecio Cunha-Neto; Christophe Chevillard
Journal:  J Infect Dis       Date:  2016-03-06       Impact factor: 5.226

6.  MicroRNA-150 inhibits expression of adiponectin receptor 2 and is a potential therapeutic target in patients with chronic heart failure.

Authors:  Simone Kreth; Carola Ledderose; Stefanie Schütz; Andres Beiras; Jens Heyn; Florian Weis; Andres Beiras-Fernandez
Journal:  J Heart Lung Transplant       Date:  2013-10-12       Impact factor: 10.247

7.  Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension.

Authors:  Christopher J Rhodes; John Wharton; Reinier A Boon; Tino Roexe; Hilda Tsang; Beata Wojciak-Stothard; Anob Chakrabarti; Luke S Howard; J Simon R Gibbs; Allan Lawrie; Robin Condliffe; Charles A Elliot; David G Kiely; Les Huson; Hossein A Ghofrani; Henning Tiede; Ralph Schermuly; Andreas M Zeiher; Stefanie Dimmeler; Martin R Wilkins
Journal:  Am J Respir Crit Care Med       Date:  2012-12-06       Impact factor: 21.405

8.  Towards a therapy for Angelman syndrome by targeting a long non-coding RNA.

Authors:  Linyan Meng; Amanda J Ward; Seung Chun; C Frank Bennett; Arthur L Beaudet; Frank Rigo
Journal:  Nature       Date:  2014-12-01       Impact factor: 49.962

Review 9.  Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine.

Authors:  Chiranjib Chakraborty; Ashish Ranjan Sharma; Garima Sharma; C George Priya Doss; Sang-Soo Lee
Journal:  Mol Ther Nucleic Acids       Date:  2017-06-12       Impact factor: 8.886

10.  Role of long non-coding RNA MIAT in proliferation, apoptosis and migration of lens epithelial cells: a clinical and in vitro study.

Authors:  Yi Shen; Ling-Feng Dong; Rong-Mei Zhou; Jin Yao; Yu-Chen Song; Hong Yang; Qin Jiang; Biao Yan
Journal:  J Cell Mol Med       Date:  2016-01-28       Impact factor: 5.310

View more
  3 in total

1.  Aerobic Exercise Inhibited P2X7 Purinergic Receptors to Improve Cardiac Remodeling in Mice With Type 2 Diabetes.

Authors:  Ting Wang; Jianmin Li; Hui Li; Xin Zhong; Luya Wang; Shujue Zhao; Xuesheng Liu; Zhouqing Huang; Yonghua Wang
Journal:  Front Physiol       Date:  2022-05-31       Impact factor: 4.755

Review 2.  Non-coding RNAs: Important participants in cardiac fibrosis.

Authors:  Yiheng Dong; Naling Peng; Lini Dong; Shengyu Tan; Xiangyu Zhang
Journal:  Front Cardiovasc Med       Date:  2022-07-28

Review 3.  The Therapeutic Roles of Cinnamaldehyde against Cardiovascular Diseases.

Authors:  Li Lu; Yuan Xiong; Juan Zhou; Guangji Wang; Bobin Mi; Guohui Liu
Journal:  Oxid Med Cell Longev       Date:  2022-10-08       Impact factor: 7.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.